Table 2. Recurrence (course and management) in patients with stage III and VI colon and rectal cancer during a 2-year follow-up strategy of conventional surveillance or additional PET-18FDG.
| Intention to | Per protocol | P | |
|---|---|---|---|
| Total, N | 130 | 125 | |
| FDG-PET | 65 | 60 | — |
| Con. | 65 | 65 | |
| Recurrence, N | 46 | 44 | |
| FDG-PET | 25 | 23 | — |
| Con | 21 | 21 | |
| Time to recurrence (month) ±s.d. | |||
| FDG-PET | 12.0±4.9 | 12.1±3.7 | |
| Con | 15.3±4.9 | 15.4±5 | 0.01 |
| Time to therapy (month)±s.d. | |||
| FDG-PET | 15.5±5 | 14.8±4.1 | 0.09 |
| Con | 17.5±6 | 17.5±6 | |
| Biopsies and surgery, N (% over total) | 27 (20.8) | 27 (21.6) | |
| PET-18FDG | 15 (23) | 15 (25) | |
| Con | 12 (18.5) | 12 (18.5) | 0.67 |
| Surgery operation, N (% over recurrences) | 17 (37) | 17 (38.6) | |
| PET-18FDG | 15 (60) | 15 (65) | |
| Con | 2 (9.5) | 2 (9.5) | <0.0001 |
| R0 curative, N (% over recurrences) | 12 (26) | 12 (27.3) | |
| PET-18FDG | 10 (40) | 10 (43.8) | |
| Con | 2 (9.5) | 2 (9.5) | <0.01 |
| Death, N (% over recurrences) | 9 (20.5) | ||
| FDG-PET | — | 3 (13) | |
| Con | — | 6 (28.5) | 0.33 |
| Time to (months) | |||
| FDG-PET | — | 8.4, 21.3, 23.2 | |
| Con | — | 9.1, 9.4, 10, 12, 13, 21.3 | |
Con=conventional, FDG-PET=18fluorodeoxyglucose positron emission tomography.